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Analysis of serum immune markers 
in seropositive and seronegative 
rheumatoid arthritis and in high-
risk seropositive arthralgia patients
Paulina Chalan1,2, Johan Bijzet1, Anke van den Berg3, Joost Kluiver3, Bart-Jan Kroesen2,4, 
Annemieke M. H. Boots1,2,* & Elisabeth Brouwer1,2,*
Presence of autoantibodies precedes development of seropositive rheumatoid arthritis (SP RA) and 
seropositive arthralgia patients (SAP) are at risk of developing RA. The aims of the study are to identify 
additional serum immune markers discriminating between SP and seronegative (SN) RA, and markers 
identifying high-risk SAP. Sera from SAP (n = 27), SP RA (n = 22), SN RA (n = 11) and healthy controls 
(n = 20) were analyzed using the Human Cytokine 25-Plex Panel. Selected markers were validated 







discriminated between the two SAP groups (AUC > 0.8), suggesting that baseline IL-5 levels may aid 
the identification of high-risk SAP.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovial mem-
brane. Synovial hyperplasia, neoangiogenesis and invasion of activated innate and acquired immune cells leads to 
an irreversible destruction of the bone and cartilage of the joint. Aggressive treatment very early in the course of 
the disease has proven effective in prevention of radiographic progression and tissue damage1–3. Based on these 
observations, postponing or even preventing RA development might become feasible by intervening before the 
onset of all clinical symptoms of RA4. First-degree relatives of RA patients and seropositive arthralgia patients 
(SAP) have been suggested to represent groups at high risk of RA development and may thus be eligible for pre-
ventive intervention5.
Seropositivity for autoantibodies such as anti-cyclic citrullinated peptide antibodies (ACPA) and/or rheuma-
toid factor (RF) is part of the diagnostic criteria for RA6. Moreover, ACPA and RF levels have a positive predictive 
value for future RA development and were detected in serum samples up to 18 years before RA diagnosis7–11. 
These autoantibodies may have a direct pathogenic effect in RA. In vitro, ACPA-containing immune complexes 
induced production of pro-inflammatory cytokines via Fcγ R-dependent triggering of macrophages12,13 and 
presence of IgM RF augmented this process14. In the pre-clinical stage of RA, emergence of ACPA and RF or 
increase of ACPA reactivity preceded the elevation of serum cytokine levels9. It has been suggested that differ-
ent inflammatory pathways are involved in the development of seronegative (SN RA) and seropositive RA (SP 
RA). Presence of autoantibodies in early RA has been shown to confer risk of more aggressive, progressive and 
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erosive disease15–20. SP RA patients have a greater need for disease-modifying anti-rheumatic drugs (DMARDs) 
or aggressive treatment16,17 and a lower chance of achieving drug-free remission20,21. Furthermore, presence of 
ACPA or RF has been associated with the development of comorbidities, such as vasculitis22 and pulmonary dis-
eases23. Worse clinical outcome suggested increased inflammatory responses in seropositive RA and prompted 
analysis of the local inflammatory site24–27. Data on the differences in the systemic inflammatory markers between 
SP and SN RA is limited28.
In the present study, we aimed to identify serum immune markers that could discriminate between recently 
diagnosed SP RA and SN RA patients. Selected markers were evaluated in independent cohorts of SP and SN RA 
patients. Secondly, we aimed to identify baseline serum markers in SAP that could discriminate between SAP 
who progressed to RA and SAP who did not progress to RA.
Results
Description of study cohorts. The SAP group was characterized by a significantly lower CRP (p = 0.0055 
and p = 0.0005, respectively), ESR (p = 0.010 and p < 0.0001, respectively) and TJC (p = 0.0002 and p = 0.0071, 
respectively) when compared to SP RA and SN RA patients (Table 1). The percentages of ACPA and RF sin-
gle- and double-positive patients were similar in the SAP and SP RA patient groups, with the majority being 
double-positive (ACPA + RF+ ). Comparison of SP with SN RA patients showed no differences between the base-
line characteristics such as age, sex, duration of symptoms until RA diagnosis, CRP, ESR, DAS28, SJC, TJC or 
the frequency of patients with radiographic changes (Table 1). The independent cohorts of recently diagnosed 
DMARD-naïve seropositive (n = 35) and seronegative (n = 12) RA patients included in the validation study did 
not differ in age, sex, symptom duration until RA diagnosis, CRP, ESR, TJC, SJC, DAS28 and presence of ero-
sions (Supplementary Table S1). Demographical and clinical characteristics of the SP and SN RA patients in the 
independent cohorts were similar, although age and ESR were lower (p = 0.039 and p = 0.029, respectively) in 
the second SN RA cohort (Supplementary Table S1). Comparison of the baseline demographical/clinical char-
acteristics of SAP progressing to RA (SAP = > RA) and SAP showed no differences between the groups. SAP 
who developed RA tended to be older at the inclusion of the study, compared to SAP not progressing during the 
follow-up (p = 0.058; Supplementary Table S2).
Unsupervised hierarchical analysis of serum immune markers separates SAP and SP RA from 
SN RA and HC. ANOVA of the 4 study groups: HC, total SAP, SP RA and SN RA revealed significant differ-
ences (p ≤ 0.002) for 22 out of the 25 markers analyzed. IL-12, IFN-γ and GM-CSF were not significantly different 
between the study groups. Unsupervised hierarchical clustering of the 22 significant markers revealed a separa-
tion into 2 clusters (Fig. 1). Fifty-six percent of all SAP and 50% of the SP RA patients form the vast majority of 
individuals in cluster 1 that is characterized by a higher expression of the 22 markers analyzed. Cluster 2 consisted 
of three subgroups with 37% of the remaining SAP and 36% of the SP-RA patients grouping together in cluster 2A 
(intermediate expression levels) and most HC (80%) clustering together in cluster 2B (relative low expression). 
Cluster 2C was characterized by intermediate expression of the serum immune markers and included 36% of the 
SN RA patients. The remaining SN RA patients were dispersed among all other clusters. Interestingly, 8/11 SAP 
who later developed RA (SAP = > RA) were included in cluster 1 (indicated by asterisks).
In order to identify the most pronounced markers per group, we selected markers that showed an increase/
decrease in expression of more than the mean ± 2SD of the HC levels in at least 45% of patients. Sixteen out of 
22 markers, showed elevated or decreased levels in ≥ 45% of patients of at least one group (Fig. 2a). The overlap 
and differences of the significantly increased or decreased markers in ≥ 45% of SAP/SP RA/SN RA are visualized 
in a Venn diagram (Fig. 2b). All markers with increased levels in SAP were also increased in SP RA, i.e. IL-1β 
HC SAP SP RA SN RA
N 20 27 22 11
Age [yrs]; mean (SD) 55.7 (7.5) 50.8 (14.4) 53.4 (12.3) 60.3 (7.5)
Gender; % female (n) 65.0 (13) 66.7 (18) 68.2 (15) 72.7 (8)
Symptom duration [mos]; 
median (range) – 24 (1–33) 6 (1–84) 5 (1–13)
ACPA positive; % (n) NR 92.6 (25) 90.9 (20) 0.0 (0)
RF positive; % (n) 15.0 (3) 88.9 (24) 81.8 (18) 0.0 (0)
CRP [mg/l]; median 
(range) NR 5.0 (5.0–29.0)* 12.5 (5.0–75.0) 17.0 (5.0–57.0)
ESR [mm/h]; median 
(range) NR 12.0 (2.0–43.0)* 21.0 (2.0–96.0) 45.0 (22.0–88.0)
TJC [n]; median (range) NR 1.0 (0.0–16.0)* 7.0 (0.0–23.0) 5.0 (0.0–27.0)
SJC [n]; median (range) NR 0.0 (0.0–0.0) 6.0 (0.0–16.0) 4.0 (0.0–14.0)
DAS28; mean (SD) NR NR 4.9 (1.6) 5.0 (1.4)
Erosions; % (n) NR - 13.6 (3) 18.2 (2)
Table 1.  Baseline demographical and clinical characteristics of the subjects included in the study. HC: 
Healthy controls; SAP: Seropositive arthralgia patients; SP RA: Seropositive rheumatoid arthritis patients; 
SN RA: Seronegative rheumatoid arthritis patients; mos: months; ACPA: Anti-cyclic citrullinated proteins 
antibodies; RF: Rheumatoid factor; CRP: C-Reactive protein; ESR: Erythrocyte sedimentation rate; TJC: Tender 
joint count; SJC: Swollen joint count; DAS28: Disease activity score 28; NR: Not reported: *Indicates p < 0.05.
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(81% and 73%, respectively), IL-2 (81% and 68%), IL-1RA (70% and 68%), IL-17 (63% and 64%), IL-4 (67% and 
50%), IL-15 (52% and 59%), and IL-2R (48% and 55%). The markers that showed a pronounced upregulation in 
SP RA but not in the other groups were IL-5 (59%), MCP-1 (50%), MIP-1α (50%), IFN-α (50%), TNF-α (45%) 
and IL-13 (45%). IL-10 serum levels were increased above the cut-off only in SN RA patients (55%). Next to the 
pronounced increase of IL-10, SN RA patients had decreased levels of Eotaxin and Rantes in 45% of patients. 
These decreases were not observed in the other groups (Fig. 2).
Validation of serum immune markers in independent SP RA and SN RA cohorts. To verify the 
differences between early SP RA and SN RA patients, we repeated the measurement of a selected (see “Statistical 
analysis” for the selection criteria) set of serum markers (IL-1β , IL-15, Eotaxin, Rantes) in independent SP RA 
and SN RA cohorts (Table 2). Significantly higher levels of IL-1β (p = 0.0125), and trends for an increase of IL-15 
and Eotaxin (p = 0.0339 and p = 0.0233, respectively, Table 2) were observed in SP RA compared to SN RA. The 
decreased levels of Rantes in SN RA compared to SP RA could not be confirmed.
Baseline levels of serum markers identifying high-risk SAP. We investigated whether the baseline 
serum markers differed between SAP who progressed to RA (SAP = > RA, median time to arthritis development 
was 8 [range 1–32] months) and SAP who did not progress to RA during the follow-up period (median follow-up 
time was 26 [range 6–33] months). Eleven of the 27 (41%) SAP progressed to SP RA (Fig. 1, Supplementary Table S2). 
SAP = > RA were characterized by higher baseline levels of IL-5, MIP-1β , IL-1RA and IL-12, compared to SAP 
who did not progress to RA (Table 3). However, when corrected for multiple comparisons (p ≤ 0.002) only trends 
for the increases in baseline IL-5, MIP-1β , IL-RA and IL-12 in SAP = > RA were noted (p = 0.007, p = 0.019, 
p = 0.028, p = 0.046, respectively). Receiver operating characteristic (ROC) analysis was used to determine if 
baseline levels of any of these 4 immune markers may discriminate between SAP who progress to RA from SAP 
who do not. A good discriminatory ability (Area Under the Curve, [AUC] > 0.8) was obtained for IL-5 (Fig. 3). 
Our data suggest that baseline IL-5 levels may help to identify SAP at risk for future RA development.
Discussion
The aims of the present study were to compare serum immune markers for their ability to discriminate between 
early SP and SN RA; and to identify serum immune markers that may predict progression to RA in SAP.
It has been suggested that RA does not begin at the level of the joint but is preceded by systemic inflamma-
tion9. This is supported by several retrospective studies that demonstrated systemic elevation of various inflam-
matory factors in the pre-RA stage10,11,29. Analysis of the markers of systemic inflammation in SAP, who are at risk 
of RA development5, has not yet been performed in a prospective study. Analysis of the local inflammation in SAP 
showed either weak30,31 or lack of32 signs of subclinical synovitis in SAP.
One of the conclusions of the present study is that the increase in markers of systemic inflammation is also 
a feature of SAP, and that the SAP immune profile is highly similar to the profile seen in SP RA patients. The 
marked overlap of serum markers in SAP and SP RA reflects a common inflammatory background between 
both conditions with increased levels of IL-1β , IL-1RA, associated with general inflammation; increased levels 
of T-cell activation markers (IL-2, IL-2R, IL-4) and increased levels of markers associated with Th17-specific 
activation (IL-17, IL-1β , IL-15). IL-1β levels were elevated in most SAP and SP RA patients. This was mirrored 
by elevations in IL-1RA. The concomitant increase of IL-1β and IL-1RA indicates activation of both pro- and 
anti-inflammatory pathways. Despite the observed increase of IL-2, known to promote Th1 and Treg cells and 
inhibit Th17 differentiation33,34, no alterations of Th1-type cytokines (IFN-γ , IL-12) or the Treg-associated IL-10 
were observed in SAP and SP RA. In contrast, IL-17 was significantly increased in these two SP groups. Thus, our 
Figure 1. Unsupervised hierarchical clustering analysis of serum markers from HC, SAP, SP RA and SN 
RA. Unsupervised hierarchical clustering (average linkage method, Euclidean distance metric) of the log2-
transformed data of 22 serum markers measured in 20 HC, 27 SAP, 22 SP RA and 11 SN RA patients. Asterisks 
indicate SAP who progressed to RA (SAP = > RA) during follow-up.
www.nature.com/scientificreports/
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Figure 2. Serum markers in patient groups compared to HC. (a) Graphs depict expression levels of log2-
transformed values in HC, SAP, SP RA and SN RA. The dotted line indicates the threshold of mean ± 2 SD of 
HC values. Horizontal lines represent mean and whiskers represent SD. Percentages above the data sets indicate 
the frequency of subjects showing expression values above/below the threshold. Differences between the groups 
were calculated using ANOVA and post-hoc Tukey’s test with p ≤ 0.002 regarded as statistically significant after 
the Bonferroni correction. Significance indicated as *** for p ≤ 0.0005 and ** for p ≤ 0.002. (b) Venn diagram 
showing differences and overlap in serum markers that were 1) statistically different between patient groups 
when compared to HC, and 2) increased/decreased above/below mean ± 2 SD of HC values in ≥ 45% SAP, SP 
RA or SN RA.
www.nature.com/scientificreports/
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results undermine the notion of RA as a Th1-mediated disease and support a role of Th17 cells in the early stages 
of SP RA pathogenesis, as previously suggested by others24,25. Moreover, increased levels of IL-1β and IL-15 in 
the periphery of SAP and SP RA may contribute to maintaining pathogenic Th17 responses, as they have been 
demonstrated to promote Th17 differentiation35 and trigger IL-17 expression36, respectively.
The second conclusion from the present study is that, in contrast to SAP and SP RA, SN RA patients showed 
a distinct immune marker profile. We have identified (main study) and confirmed (validation study) IL-1β as an 
immune marker differentially expressed in SP RA and SN RA. This observation suggests that the pathological 
pathways involving blood monocytes may be activated in seropositive but not seronegative RA, as IL-1β has been 
reported to be expressed by this cell type (as well as tissue macrophages and dendritic cells) in response to stim-
ulation37. Also, IL-15 and Eotaxin may be useful in discriminating between SP and SN RA as these markers, but 
not CCL5, were similarly modulated in the independent cohorts.
Despite the differences in pro- and anti-inflammatory markers between SP RA and SN RA, clinical features 
of these groups at baseline were similar. Most available studies showed that, in line with our cohorts, all or most 
of the baseline demographical and clinical characteristics were similar between ACPA+ and ACPA- RA patie
Validation cohorts Main cohorts
SP RA SN RA p-value SP RA SN RA p-value
N 35 12 – 22 11 –
IL-1β [pg/mL(log2)]; median (IQR) 4.83 (1.01) 4.35 (0.37) 0.0125 7.10 (4.49) 3.98 (1.96) 0.0044
IL-15 [pg/mL(log2)]; median (IQR) 4.82 (0.66) 4.45 (0.55) 0.0339 7.95 (6.13) 4.18 (5.03) 0.0016
Eotaxin [pg/mL(log2)]; median (IQR) 6.51 (0.70) 5.15 (3.99) 0.0233 8.03 (4.20) 6.48 (8.57) 0.0031
Rantes [pg/mL(log2)]; median (IQR) 12.99 (0.88) 13.06 (0.38) 0.8836 12.45 (0.63) 12.02 (5.72) 0.0111
Table 2.  Results of the validation study in independent SP RA and SN RA cohorts. SP RA: Seropositive 
rheumatoid arthritis patients; SN RA: Seronegative rheumatoid arthritis patients; IQR: Interquartile range. 
SP RA and SN RA cohorts from the validation or the main study were compared with Mann-Whitney test. 






SAP = > RA 
(n = 11) p-value
[pg/mL(log2)]; median (IQR)
IL-5 − 4.00 (2.66) − 0.54 (1.65) 0.007
MIP-1β 7.50 (1.77) 8.24 (1.99) 0.019
IL-1RA 7.61 (1.84) 9.02 (3.61) 0.028
IL-12 7.95 (0.36) 8.15 (1.41) 0.046
IL-2 4.34 (2.81) 5.22 (4.09) 0.109
IL-6 2.23 (3.69) 3.03 (2.13) 0.109
IL-1β 6.66 (2.82) 7.04 (4.25) 0.132
IL-7 3.32 (3.08) 5.06 (4.92) 0.167
IL-2 R 7.96 (1.14) 8.37 (1.87) 0.175
Eotaxin 7.81 (2.10) 8.86 (2.11) 0.199
IL-13 1.68 (1.74) 3.32 (2.18) 0.204
MIP-1α 6.84 (1.33) 6.99 (2.82) 0.267
IFN-α 5.20 (2.54) 5.63 (2.85) 0.275
IL-17 3.70 (7.02) 4.78 (1.98) 0.286
TNF-α 0.98 (4.78) 1.32 (2.83) 0.311
IL-15 6.49 (2.14) 7.03 (4.65) 0.336
IFN-γ − 1.74 (0.74) − 1.00 1.22) 0.388
IL-10 − 0.33 (5.47) 0.70 (2.61) 0.401
GM-CSF 4.60 (3.70) 5.00 (1.54) 0.412
MCP-1 10.42 (0.89) 10.69 (2.23) 0.430
IP-10 3.98 (0.73) 4.34 (1.72) 0.570
Rantes 12.32 (0.37) 12.33 (.029) 0.604
IL-8 8.62 (1.87) 9.43 (3.04) 0.639
MIG 3.77 (1.95) 3.12 (2.12) 0.902
IL-4 4.21 (2.40) 3.94 (3.97) 1.000
Table 3.  Baseline levels of serum markers in SAP who progressed to RA and SAP not progressing. SAP: 
seropositive arthralgia patients; IQR: Interquartile range. SAP groups were compared using Mann-Whitney test. 
P ≤ 0.002 was considered statistically significant.
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nts16,17,24,26,27. However, significantly increased CRP, ESR and DAS28 levels, and increased radiographic damage 
in ACPA+ patients have also been reported16,18,19,26. It has been suggested that differences in the pathogenesis and 
prognosis between SP RA and SN RA are the consequence of different pathological events at the inflammatory 
site. However, most studies reported similar levels of inflammatory markers in the joints of SP RA and SN RA, 
with significantly increased levels being observed only for CCL20, IL-10, IL-1β and IL-1724,25 in ACPA+ RA. 
Increased lymphocytic infiltration, expression of T-cell markers and lymphocyte chemoattractant in the syn-
ovium of ACPA+ compared to ACPA− RA patients has been reported26. These differences in synovial infiltration 
between ACPA+ and ACPA− RA patients, however, were not confirmed by three other studies24,25,27. Also, the 
numbers of B-cells, plasma cells in the synovium24,26,27 or B-cells in synovial fluid and blood38 were found to be 
similar between seropositive and seronegative RA. Thus, there is no consensus on synovial markers discrimi-
nating between SP and SN RA. Our study is the first to describe specific differences in serum immune markers 
in SP RA and SN RA. Deane et al. reported that the percentage of pre-diagnosis samples positive for cytokines 
was lower in patients who later developed SN RA as compared to the percentage of cytokine positive samples in 
patients who later developed SP RA28. ACPA/RF-containing immune complexes can trigger cytokine production 
via Fcγ R-crosslinking, as demonstrated in vitro12–14. We hypothesize that this mechanism is responsible for the 
observed more pronounced expression of serum markers in SP RA compared to SN RA. The qualitative differ-
ences between SP RA and SN RA indicate the importance of stratifying RA patients according to the autoanti-
body status in studies investigating pathological pathways involved in RA and in clinical trials.
It is well known that rheumatoid factor, particularly IgM-RF, may interfere with the assay outcome by 
false-positive binding. Therefore, we explored this issue by measuring levels of several immune markers in a 
serum sample with high RF level, before and after RF precipitation using polyethylene glycol (PGE 6000)39. RF 
blocking had limited effects on the detection of the cytokines tested (data not shown). Thus, similar to others29, 
we decided to not incorporate the RF blocking step in our procedures. However, possible interference with RF can 
thus not be fully excluded and is a limitation of the current study.
The third conclusion of this study is that baseline levels of IL-5 may aid in identifying high risk SAP. The per-
centage of SAP who developed RA in our cohort was similar to that reported by others30,40,41. The role of IL-5 in 
RA; a Th2-specific cytokine primarily involved in regulation of eosinophil functions in the tissue42, is ill-defined. 
IL-5 was not present in the synovium and rheumatoid nodules of RA patients43,44. Implications of the increase 
of systemic IL-5 levels in SAP = > RA, a serum marker that was also found elevated in 59% of SP RA, would 
require further studies. So far, the identification of high risk SAP relied mostly on demographic (i.e. presence of 
the first-degree relative with RA, alcohol non- use) and clinical variables (i.e. duration of the morning stiffness 
≥ 1 hour, symptoms and VAS pain ≥ 50)40. Recently, the combination of a type I IFN signature with a B celllow 
signature was found to predict RA development in SAP40,45. Our data suggest that measurement of serum IL-5 
may add to current prediction models.
Methods
Subjects. In this comparative study we included 22 recently diagnosed SP RA (ACPA+ and/or RF+ ) patients; 
11 recently diagnosed SN RA (ACPA− and RF− ) patients; 27 SAP and 20 healthy controls (HC, Table 1). For val-
idation purposes, we included serum samples from 2 independent cohorts of SP RA (n = 35) and SN RA (n = 12, 
Supplementary Table S1). Inclusion criteria for the prospective SAP cohort, other than seropositivity, were the 
presence of arthralgia (tender joint count [TJC] ≥ 1) but no diagnosis of arthritis (swollen joint count [SJC] = 0). 
The diagnosis of seropositive arthralgia was made by a trained rheumatologist (EB), after patients with joint 
complaints were referred to our early arthritis clinic or early arthritis recognition clinic by their general practi-
tioner. SAP were seen every 6 months or had a visit scheduled when their joint complaints progressed, including 
swelling of the joints. Upon diagnosis of arthritis the prospective follow-up in the SAP cohort was terminated. 
Figure 3. Receiver operating characteristic curves (ROC) for selected baseline serum markers in 
SAP = > RA and SAP not progressing. ROC analysis and area under the curve of ROC curves was performed 
for 4 immune markers whose baseline levels showed trends towards a significant difference in the comparison 
of SAP = > RA and SAP not progressing (as demonstrated in Table 3).
www.nature.com/scientificreports/
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Early RA patients, fulfilling the 1987 or 2010 American College of Rheumatology (ACR) classification criteria for 
RA were included at time of diagnosis and these patients did not receive disease modifying anti-rheumatic drugs 
(DMARDs). Both SAP and RA were treated with non-steroidal anti-inflammatory drugs (NSAIDs) only. At the 
time of inclusion recently diagnosed RA and SAP were assessed for the presence of radiographic damage. Healthy 
subjects were not recently vaccinated, did not have an infection and did not use immunosuppressive drugs at the 
time of blood withdrawal, as assessed by a health questionnaire. All participants gave their informed consent and 
the study was approved by the local medical ethics committee (UMC Groningen). All experimental protocols 
were carried out in accordance with the approved guidelines and were approved by the ethical committee of UMC 
Groningen.
Demographical and clinical characteristics of all study participants are shown in Tables 1, Supplementary 
Tables S1 and S2. Eleven of the SAP (41%) progressed to RA (indicated as SAP = > RA) over a median follow-up 
of 8 (range 1–32) months. The median follow-up time for the non-progressing SAP (until the last visit or until 
December 2014) was 26 (range 6–33) months.
ACPA serum levels were determined by anti-IgG CCP fluorescent enzyme immunoassay using Phadia 250 
System (Thermo Fisher Scientific, Uppsala, Sweden) and serum levels ≥ 10 IU/ml were considered as positive. 
Total RF serum levels were determined by turbidimetry using a modular analyzer (Roche, Mannheim, Germany) 
and serum levels ≥ 15 IU/ml were considered positive.
Measurement of serum immune markers. Peripheral blood was collected in anticoagulant-free tubes, 
centrifuged (at 1200 g for 10 min) and serum was stored at − 20 °C until analysis. Serum immune markers were 
quantified with the Human Cytokine 25-Plex Panel (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Custom-made Luminex immunoassay (Life Technologies) was used for the detection 
of IL-1β , IL-15, Eotaxin and Rantes in the validation cohorts. Samples were measured using Luminex 100 System 
(Luminex, Austin, Tx, USA) and data were analyzed with StarStation software, version 2.3 (AppliedCytometry, 
Birmingham, UK). The following markers were assessed in the main study: IL-1β , IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IFN-α , IFN-γ , GM-CSF, TNF-α , IL-1 receptor antagonist (IL-1RA), 
IL-2 R, Eotaxin (CCL11), IL-8, IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), MIP-1α (CCL3), MIP-1β 
(CCL4) and Rantes (CCL5).
Statistical analysis. Demographical and clinical characteristics were compared with ANOVA or 
Kruskall-Wallis test for continuous data with normal and non-normal distribution, respectively. Categorical 
data were analyzed using chi-squared test. Data obtained from 2 groups were compared with Mann-Whitney or 
Fisher’s exact tests. P < 0.05 was considered statistically significant. For all analyses, data were log2-transformed 
in order to approach a Gaussian distribution. Differences between the groups were analyzed with ANOVA and a 
Tukey’s post-hoc test. Differences between the 2 SAP groups were compared using Mann-Whitney test. In order 
to adjust for multiple comparisons, results were considered statistically significant when p ≤ 0.002 (Bonferroni 
correction). Cytokines for the validation study were chosen according to the following criteria: 1) their levels 
were significantly different between SP RA and SN RA in the main cohort, 2) ≥ 45% of SP RA and SN RA patients 
showed expression levels above or below mean ± 2 standard deviations (SD) of the HC values and 3) size of the 
independent sample cohort required to obtain the desired power (1-sided, sensitivity 90%, confidence intervals 
95%) was sufficient. Differences between the groups of SP RA and SN RA from the independent cohorts or from 
the main cohorts were compared using Mann-Whitney test (after multiple testing correction, p ≤ 0.0125 was 
considered statistically significant). Analyses were performed with IBM SPSS Statistics 20 (SPSS, Chicago, IL, 
USA). Hierarchical clustering analysis was done with Genesis 1.7.6 software46 using Euclidean distances and 
average linkage.
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